NDAORALTABLETPriority Review
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
10
Clinical Trials (5)
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
Started May 2023
44 enrolled
Smallpox
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia
Started Dec 2018
0Adenovirus
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
Started Sep 2015
6 enrolled
Cytomegalovirus DiseaseKidney Transplant Infection
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
Started Sep 2015
5 enrolled
Cytomegalovirus Disease
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
Started Oct 2014
0Ebola Virus
Loss of Exclusivity
LOE Date
Oct 10, 2034
104 months away
Patent Expiry
Oct 10, 2034
Exclusivity Expiry
Jun 4, 2028